annb0t
Top 20
MELBOURNE, Australia, June 3, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that it has completed the submission of a Biologics License Application (BLA) to the United States (U.S.) Food and Drug Administration (FDA) for its investigational radiodiagnostic PET[1] agent, TLX250-CDx (Zircaix®[2], 89Zr-DFO-girentuximab), for the characterisation of renal masses as clear cell renal cell carcinoma (ccRCC). (PRNewsfoto/Telix Pharmaceuticals Limite...
>>> Read more: Telix Completes TLX250-CDx (Zircaix®) BLA Submission for Kidney Cancer Imaging
>>> Read more: Telix Completes TLX250-CDx (Zircaix®) BLA Submission for Kidney Cancer Imaging
